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ABSTRACT

THE EFFECTS OF 3-PHOSPHOGLYCERATE AND OTHER
METABOLITES ON THE ACTIVATION OF AMPACTIVATED PROTEIN KINASE BY
LKB1/STRAD/MO25

William J. Ellingson
Department of Physiology and Developmental Biology
Master of Science

Skeletal muscle contraction results in the phosphorylation and activation of the
AMP-activated protein kinase (AMPK) by an upstream kinase, AMPKK. The
LKB1/STRAD/MO25 complex (LSMK) is the major AMPKK in skeletal muscle;
however, LSMK activity is not increased by muscle contraction. This relationship
suggests that phosphorylation of AMPK by LSMK during skeletal muscle contraction
may be regulated by allosteric mechanisms. In this study we tested an array of
metabolites including glucose-6-phosphate (G6P), fructose-6-phosphate (F6P),
fructose 1,6-bisphosphate (F1,6-P2), 3-phosphoglycerate (3PG), glucose-1-phosphate
(G1P), glucose-1,6-bisphosphate (G1,6-P2), adenosine diphosphate (ADP), carnitine
(Carn), acetyl-carnitine (Acarn), inosine monophosphate (IMP), inosine, and ammonia
to test for allosteric regulation. We found that 3PG stimulated LSMK activity and

allowed for increased AMPK phosphorylation. 3PG did not stimulate LSMK activity
toward the peptide substrate LKB1tide. The stimulatory effect that 3PG has with
AMPK activation was determined to be an allosteric effect. These results have
identified 3PG as an AMPK-specific allosteric regulator of AMPK activation by
LSMK.
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Introduction
The AMP-activated protein kinase (AMPK) is a master metabolic regulator
found to regulate fatty acid oxidation and glucose uptake. AMPK is able to sense the
rapid rise in the AMP-to-ATP ratio that accompanies skeletal muscle stimulation, and
as a result, become active. AMPK is activated by both AMP and an upstream kinase,
AMPKK, composed of three complexed proteins, LKB1, STE-related adaptor
(STRAD), and mouse protein 25 (MO25). During a bout of exercise, AMPK
activation increases in skeletal muscle while the apparent AMPKK activity does not
change. During muscle contraction, changes are also observed in the content of
intracellular skeletal muscle metabolites and lipids. A possible explanation for why no
increase in AMPKK activity is observed during endurance exercise is that AMPKK
activity is altered by the change in the intramuscular metabolites and lipids, and not
via covalent modification. This could be accomplished by either allosteric effects on
AMPKK or at the substrate level, making AMPK a better substrate for AMPKK. This
study will investigate whether the changes in the intracellular environment during
skeletal muscle exercise will have allosteric effects on AMPKK.

AMPK
AMPK is a heterotrimeric protein containing α, β, and γ subunits. Each
subunit can be found in different isoforms: the α subunit can be either α1 or α2; the β
subunit can be either β1 or β2; and the γ subunit can be either γ1, γ2, or γ3. The most
common isoforms in most cells are the α1, β1, and γ1. However, in skeletal and
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cardiac muscle, α2, β2, γ2, and γ3 are also expressed (6, 44, 48). The α subunit
contains the catalytic
domain, where AMPK activation occurs at threonine-172 by an upstream
AMPK kinase (AMPKK) (21). The γ subunit contains four specialized Cystathione
Beta Synthase (CBS) domains, which create two AMP binding sites termed Bateman
domains. The binding of AMP to the first Bateman domain works cooperatively to
increase the binding affinity of a second AMP. Once AMP is bound, the α subunit is
then exposed for phosphorylation at threonine-172.

AMPK Activation
AMPK activation is a two-step process: first, AMP binding to the Bateman
domains of the γ subunit, and second, phosphorylation at threonine-172 of the α
subunit. AMPK monitors the AMP:ATP ratio within the cells of the body; when
AMP levels rise and ATP levels decline, more AMP is available for binding to the
Bateman domains. Due to this relationship, AMPK can be chemically stimulated by
5-amino-4-imidazolecarboxamide riboside (AICAR), which after entering the cell is
converted into an AMP analog 5-amino-4-imidazolecarboxamide ribotide (ZMP) (26).
AMPK activation can occur during muscle contraction (55). During muscle
contraction, there is a rapid change in the AMP-to-ATP ratio. This rapid rise in AMP
will allosterically activate AMPK (5, 8, 21). AMPK activation during exercise or
artificial electrical stimulation is dependent on the muscle work rate (31, 38). At low
work rates in humans, AMPK is not activated, whereas higher work rates will cause
AMPK activation (15, 57).
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Regulation of Fatty Acid Oxidation by AMPK
Activated AMPK modulates fatty acid oxidation through its inhibitory effects
on acetyl-CoA carboxylase (ACC) (35, 55, 56). ACC is a major component of the
fatty acid synthesis pathway. AMPK stops ACC activity upon AMPK
phosphorylation of ACC. When ACC is inactivated, levels of malonyl-CoA, a product
of ACC, decrease. This drop in malonyl-CoA concentration removes the inhibitory
effects that malonyl-CoA has on the enzyme carnitine palmitoyltransferase 1 (CPT-1).
CPT-1 participates in the rate limiting step of fatty acid transport into mitochondria for
oxidation. Thus, by removing the inhibitions on CPT-1 through ACC inactivation,
AMPK regulates the degree to which a cell undergoes fatty acid oxidation.

Regulation of Glucose Uptake by AMPK
The skeletal muscle glucose transporter, GLUT-4 is an insulin-sensitive
transporter, which resides in two locations in the muscle (16, 17, 23, 28). In the low
insulin state, GLUT-4 resides in microvesicles beneath the sarcolemma and T-tubule
membranes. In response to contraction, these transporters are then translocated to the
membranes of the T-tubules and sarcolemma, allowing for increased glucose transport
into the muscle fiber. AMPK has been identified as a major modulator of contractioninduced GLUT-4 translocation (2, 22, 33).

LKB1 as an AMPKK
The protein LKB1 has been found to have AMPKK capabilities. LKB1 was
first characterized as a tumor-suppressor kinase. LKB1 is a serine/threonine kinase
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also known as STK11, which was identified in 1998 to be the gene that is mutated in
Peutz–Jeghers syndrome (PJS) (25). PJS individuals develop benign polyps in the
gastrointestinal tracts with increased probability of developing malignant tumors in
other tissues such as the liver. In 2003, LKB1 was shown to be activated through its
interaction with STE20-related adaptor (STRAD) (1) and mouse protein 25 (MO25)
(3). It appears as though STRAD acts as a cytoplasmic anchor, while MO25 acts as a
scaffolding protein for the LKB1/STRAD/MO25 complex. Hawley et al. also found
in 2003, that the LKB1/STRAD/MO25 complex has the ability to be a constitutively
active AMPK kinase, phosphorylating AMPK at threonine-172 (20). They found
through western blotting that when the three proteins were present, phospho-AMPK
(P-AMPK) levels were high, whereas in the absence of one or more of the proteins, PAMPK was lowered. The lowest P-AMPK levels were found when LKB1 was
removed through immunoprecipitation.
The role of LKB1 as the major AMPKK was demonstrated through a muscle
specific LKB1 knockout (41). Mice that expressed the LKB1 knockout in muscle
tissue experienced an enormous decrease in the production of P-AMPK and a decrease
in phosphorylation of the downstream target of AMPK, ACC. Glucose uptake
stimulated by AICAR and contraction was inhibited. These data demonstrate the
integral role that LKB1 has in AMPKK function.

AMPKK and Exercise
Single bouts of endurance exercise and muscle stimulation have been shown to
increase AMPK activity (22, 30, 40, 51) as well as P-AMPK abundance (12, 36) in
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non-trained tissues as well as trained tissues (12, 29, 36). Along with P-AMPK,
endurance training will increase the abundance of the proteins LKB1 and MO25 (29,
46, 47). STRAD has not been shown to increase during endurance training due to an
unavailability of STRAD antibodies for Western blotting. Due to these adaptations
during endurance exercise and training, it is thought that AMPKK activity or LKB1
activity would likewise increase. However, no such increase has been found to be
caused by a bout of contraction in non-trained tissues (29, 40), and trained tissues (29,
46, 47). There is a significant decrease in apparent AMPKK activity of trained tissues
compared with non-trained tissues (29), and increased training duration showed
further declines in AMPKK activity (47). These seemingly paradoxical findings
suggest that AMPKK is activated during contraction by mechanisms other than
covalent modification (29). It is possible that during contraction, the changes in the
intracellular environment, particularly the concentrations of metabolites, lipids and
other compounds, may either activate AMPKK allosterically or allow for AMPK to
become a better substrate for AMPKK.

Metabolite Changes During Exercise
Upon skeletal muscle contraction, intramuscular changes occur, many of which
involve energy production and regulation. When the process of glycolysis is activated
upon skeletal muscle excitation and contraction, many of the glycolytic intermediates
have changes in their concentrations. Molecules involved in glycogenolysis also
change with contraction. Glucose 6-phosphate (G6P) concentrations increase (24, 32,
37, 42) from as low as 0.06 mM to 1.96 mM (27), fructose-6-phosphate (F6P) will
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increase (37, 53, 54) from at least 0.018 mM to 0.134 mM (24), fructose-1,6bisphosphate (F1,6-P2) will increase (42) from as low as 0.004 (27) to 0.20 mM (54),
and 3-phosphoglycerate (3PG) will increase from as low as 0.4 mM to 1.38 mM (14).
Glucose-1-phosphate (G1P) and glucose-1,6-diphosphate (G1,6-P2) are both involved
in glycogen depletion and synthesis. G1P will change from 0.13 mM to 0.39 mM
(24), while G1,6-P2 will increase from as low as 0.015 mM (53) to 0.120 mM (42).
Adenosine diphosphate (ADP) (24, 37, 43), carnitine and its acylated form,
acetyl-carnitine (7, 39, 50) levels all change with skeletal muscle exercise. ADP, a
product of ATP breakdown (ATP → ADP + Pi) and involved in the myokinase
reaction (2ADP → ATP + AMP), increases from 0.39 mM (43) to 0.81 mM (37).
Carnitine and acetyl-carnitine are both involved in fatty acid oxidation. Carnitine will
decrease from 3.18 mM to 0.92 mM (39) while acetyl-carnitine will increase from
0.46 mM (50) to 3.62 mM (39).
The purine nucleotide cycle (PNC) is important in maintaining a high cellular
energy store. Members of the PNC including inosine monophosphate (IMP) (24, 58,
59), inosine (13, 19, 59), and ammonia (24, 43), have been found to increase with
exercise. IMP, the deaminated version of AMP, increases from at least 0.2 mM (59)
to at least 3.4 mM (58). Inosine, a precursor to adenosine and uric acid, can increase
from barely detectable levels to 0.25 mM (13). Ammonia, part of the PNC and
nitrogen cycle, can increase from 0.05 mM to 0.51 mM (24).
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Sphingolipids and Exercise
One of the major fractions of cellular phospholipids is sphingolipids.
Sphingolipids are part of a sphingolipid-sphingomyelin transmembrane signaling
pathway. Their hydrolysis yields ceramide and phosphorylcholine. Ceramide has
been recognized as the second messenger in the pathway. Ceramide is composed of a
sphingoid base and a long-chain fatty acid joint in an amide bond. Ceramide can also
be synthesized de novo from serine and palmitoyl-CoA, a known AMPKK inhibitor
(45). Sphinganine is a key intermediate in the synthesis of ceramide from serine and
palmitoyl-CoA. Once ceramide is synthesized, it can then be broken down to
sphingosine and other down stream products.
Ceramide has been speculated to be involved in insulin sensitivity (18).
Ceramide levels are elevated in obese, insulin-resistant Zucker rats (49). Further
studies have shown that in the presence of ceramide, GLUT-4 translocation to cell
membranes is inhibited (4, 52). Moreover, the post-exercise elevation in glucose
uptake by different skeletal muscle types in rats was found to be inversely related to
the total content of ceramide in the muscle (9).
In resting rat skeletal muscle, the three most prominent fatty acid side chains
on ceramide are stearic (C18), palmitic (C16), and oleic (C18:1) acids. Concentrations
of these ceramide fatty acids and others decrease with exercise. C18 levels decrease
from at least 55.9 µM (9) to 18.0 (11) µM, C16 decreases from about 45.0 µM (9) to
13.6 µM (11), and C18:1 decreases from 33.0 µM (11) to 11.61 µM (9). In addition,
levels of sphinganine and sphingosine increase with exercise. Sphinganine will
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increase in intramuscular concentration from about 1.6 µM to 17.0 µM, and
sphingosine will increase from about 3.0 µM to 15.0 µM (10).

Hypothesis
Given that exercise increases both AMPKK and P-AMPK protein abundance,
AMPKK is likely more active with muscle excitation. However, current data show
that this is not the case. It is hypothesized that the changes to the intracellular
environment during contraction will activate AMPKK through allosteric mechanisms,
thus giving an explanation for both the apparent drop in AMPKK activity and rise in
AMPK phosphorylation during skeletal muscle exercise.

Proposed Experiments
1) AMPKK activity assays using recombinant LKB1/STRAD/MO25 and
recombinant α2β2γ2-AMPK will be performed in the individual presence of
either G6P, F6P, F1,6-P2, 3PG, G1P, G1,6-P2, ADP, carnitine, acetylcarnitine, inosine, IMP, ammonia, C16 ceramide, sphinganine, or sphingosine
to test their effects at both resting and exercising concentrations.
2) Phospho-AMPK (P-AMPK) activity assays will be performed for those
compounds that exhibit an effect on AMPKK activity. The results of this will
show whether the activation or inhibition seen in Experiment 1 is affecting the
AMPKK complex or AMPK.
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3) AMPKK activity assays will be performed using recombinant α1β1γ1-AMPK
for the compounds that affect AMPKK activity. This will demonstrate
whether the effect is specific to muscle tissue or not.
4) For the compounds used in Experiment 3, Western blots will be performed to
give further evidence for its ability to alter AMPK phosphorylation via
AMPKK.
5) To elucidate whether the effects of the compounds used in Experiment 3 are
experienced through allosteric mechanisms, further enzyme activity assays will
be performed.

Methods
Buffers. When applicable, dithiothreitol (DTT) and [γ32]ATP are added just
prior to use. AMPK Storage Buffer: 50 mM Tris-HCl, 250 mM Mannitol, 1 mM
EDTA, 1mM EGTA, 1 mM DTT, 0.02% (w/v) Brij-35, 10% v/v glycerol, pH 7.4 at
4˚C. AMPK Phosphorylation Buffer: 100 mM Hepes, 200 mM NaCl, 20% glycerol, 2
mM EDTA, 12.5 mM MgCl2, 0.5 mM AMP, 0.5 mM ATP, 2.0 mM DTT, pH 7.0.
AMARA Phosphorylation Buffer: 40 mM Hepes, 80 mM NaCl, 8% glycerol, 0.8 mM
EDTA, 0.8 mM DTT, 5 mM MgCl2, 0.2 mM AMP, 0.2 mM ATP, 0.33 mM AMARA
peptide, 0.05 µCi/µl [γ32]ATP, pH 7.0. Laemmli’s Buffer: (34). PBS: 140 mM NaCl,
2.7 mM KCl, 2.1 mM KH2PO4, 9.9 mM Na2HPO4, pH 7.3. PBST: PBS with 1%
Tween-20.
AMPKK Activity Assay. AMPKK activity is measured in a two-step assay. In
the first step, AMPK is phosphorylated and activated by AMPKK. In the second step,
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P-AMPK phosphorylates AMARA peptide (21). Recombinant α1β1γ1 or α2β2γ2AMPK was diluted 1:19 in water. Recombinant LKB1/STRAD/MO25 (0.86 µg/µl) is
diluted 1:39 in AMPK storage buffer. The testing compounds, G6P, F6P, F1,6-P2,
3PG, G1P, G1,6-P2, ADP, carnitine, acetyl-carnitine, inosine, IMP, ammonia, C16
ceramide, sphingosine, and sphinganine are dissolved in water at five times the desired
final concentration during the first step of the reaction. For the assay, 4 µl of AMPK
phosphorylation buffer is mixed with 2 µl of diluted recombinant AMPK, 2 µl of the
testing compound, and 2 µl of AMPKK and allowed to incubate for 20 min at 30°C.
After the incubation, 15 µl of AMARA phosphorylation buffer is added to the mixture
to start the second step of the assay and allowed to incubate for an additional 10 min.
At the conclusion of the 10 min, the reaction is stopped by spotting on a 1cm2 piece of
Whatman P81 filter paper with 15 µl of the final reaction mixture. Filter papers are
allowed to absorb for 15 sec and then placed in 100 ml of 1% phosphoric acid. The
papers are washed in the acid six times and then dried with a brief rinse of acetone.
They are allowed to dry and then placed in 3 ml of Ecolite scintillation fluid and
counted for 1 min.
P-AMPK Activity Assay. Same as the AMPKK activity assay, but with the
testing compound being added during the second reaction instead of the first. To
compensate for the addition at this step, 13 µl of AMARA phosphorylation buffer is
added, and all concentrations are adjusted to have equal final concentrations as in the
AMPKK activity assay.
Western Blot. The first step of the AMPKK assay is performed. After the 20
min incubation period, the reaction is stopped by addition of diluted 4 x Laemmli’s
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buffer and water (1:1:2). The reaction mixtures are then separated by SDS-PAGE at
200 V for 35 minutes in 7.5% Tris-HCl, 50 µl well Ready Gels. Proteins are
transferred from the gels to nitrocellulose membranes at 100 V for 50 min.
Membranes are blocked in PBST and 5% Blotting Grade Blocker Non-Fat Dry Milk
for 1h. Membranes are incubated overnight at 4 C in PBST, 5% blocking milk, and
first antibodies. After incubation with the first antibody, membranes are washed twice
with PBST for 10 minutes and twice with PBS for 5 minutes. Membranes are then
incubated for 1 hour at room temperature in PBST, 3% blocking milk, and a second
antibody. Following incubation with the second antibody, membranes are washed
twice with PBST for 10 minutes and twice with PBS for 5 minutes. Membranes are
covered with ECL Western Blotting Detection Reagent, enclosed in plastic wrap, and
visualized on Hyperfilm ECL High Performance Chemiluminescence film. Relative
amounts of protein are quantified by measuring spot size and intensity with
AlphEaseFC Software.
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THE EFFECTS OF 3-PHOSPHOGLYCERATE AND OTHER METABOLITES
ON ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE BY
LKB1-STRAD-MO25

ABSTRACT
Skeletal muscle contraction results in the phosphorylation and activation of the AMPactivated protein kinase (AMPK) by an upstream kinase, AMPKK. The LKB1STRAD-MO25 complex is the major AMPKK in skeletal muscle; however, LKB1STRAD-MO25 activity is not increased by muscle contraction. This relationship
suggests that phosphorylation of AMPK by LKB1-STRAD-MO25 during skeletal
muscle contraction may be regulated by allosteric mechanisms. In this study we tested
an array of metabolites including glucose-6-phosphate (G6P), fructose-6-phosphate
(F6P), fructose 1,6-bisphosphate (F1,6-P2), 3-phosphoglycerate (3PG), glucose-1phosphate (G1P), glucose-1,6-bisphosphate (G1,6-P2), adenosine diphosphate (ADP),
carnitine (Carn), acetyl-carnitine (Acarn), inosine monophosphate (IMP), inosine, and
ammonia for allosteric regulation. We found that 3PG stimulated LKB1-STRADMO25 activity and allowed for increased AMPK phosphorylation. 3PG did not
stimulate LKB1-STRAD-MO25 activity toward the peptide substrate LKB1tide.
These results have identified 3PG as an AMPK-specific regulator of AMPK
phosphorylation and activation by LKB1-STRAD-MO25.

Key Words: AMPK; AMPKK; metabolism; glycolysis; STK11
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INTRODUCTION
The AMP-activated protein kinase (AMPK) is a master metabolic regulator
found to regulate fatty acid oxidation (20, 43, 44) and glucose uptake (2, 11, 17, 20) in
skeletal muscle. AMPK senses changes in AMP-to-ATP ratios. An increase in AMP
concentration causes a conformational change in AMPK. This occurs when 2 AMP
molecules bind to 4 cystathione β-synthase (CBS) domains on the γ-subunit of AMPK
(1, 31). This conformational change allows AMPK to be phosphorylated, and
consequently activated, by an upstream kinase, AMPKK, composed of three
complexed proteins, LKB1, STE-related adaptor (STRAD), and mouse protein 25
(MO25) (9, 32, 45). AMPK must be phosphorylated by AMPKK on its activation
loop at Thr172 for full activation.
AMPK is activated by the constitutively active kinase complex LKB1STRAD-MO25 during skeletal muscle contraction (28, 29). AMPK activation
increases during a bout of skeletal muscle contraction caused by endurance exercise
(41), in situ stimulation (14, 15, 28, 39), or in vitro stimulation (11), while the
apparent AMPKK activity does not change (14, 28). Furthermore, studies showing
skeletal muscle contraction of both trained humans (21) and rats (14) yielded increases
in AMPK phosphorylation in the face of no change or decreased measurable AMPKK
activity. This relationship seems contradictory, given that one would expect an
increased AMPKK activity to accompany the increased AMPK phosphorylation.
These findings imply that muscle AMPKK becomes more active during contraction by
mechanisms other than covalent modifications which could be detected in extracts of
the muscle homogenate. Since LKB1-STRAD-MO25 can phosphorylate at least 14

22

downstream kinases, substrate level regulation for each of these is conceivable.
Allosteric activation of AMPK phosphorylation by undefined modulators must also be
considered as a mechanism of specific regulation of downstream targets.
To explore this issue, we considered changes that occur in the skeletal muscle
metabolite concentrations during contraction. Previous studies have demonstrated
exercise-induced changes in the concentrations of glucose-6-phosphate (G6P) (12, 13,
16, 26, 30), fructose-6-phosphate (F6P) (12, 26, 41, 42), fructose-1,6-bisphosphate
(F1,6-P2) (13, 30, 42), 3-phosphoglycerate (3PG) (6), glucose-1-phosphate (G1P) (12),
glucose-1,6-bisphosphate (G1,6-P2) (30, 41), adenosine diphosphate (ADP) (12, 26,
33), carnitine (Carn) (3, 27, 38), acetyl-carnitine (Acarn) (3, 27, 38), inosine
monophosphate (IMP) (12, 46, 47), inosine (5, 8, 47), and ammonia (12, 33). We
hypothesized that one or more of these metabolites would demonstrate allosteric
control on AMPK activation by interacting either directly on the LKB1-STRADMO25 complex, or on AMPK itself, making it a better substrate for phosphorylation
by LKB1-STRAD-MO25.

MATERIALS AND METHODS
Buffers. When applicable, dithiothreitol (DTT) and [γ32P]ATP are added just
prior to use. AMPK Storage Buffer: 50 mM Tris-HCl, 250 mM mannitol, 1 mM
EDTA, 1mM EGTA, 1 mM DTT, 0.02% (w/v) Brij-35, 10% v/v glycerol, pH 7.4 at
4˚C. AMPK Phosphorylation Buffer: 100 mM Hepes, 200 mM NaCl, 20% glycerol, 2
mM EDTA, 12.5 mM MgCl2, 0.5 mM AMP, 0.5 mM ATP, 2.0 mM DTT, pH 7.0.
AMARA Phosphorylation Buffer: 40 mM Hepes, 80 mM NaCl, 8% glycerol, 0.8 mM
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EDTA, 0.8 mM DTT, 5 mM MgCl2, 0.2 mM AMP, 0.2 mM ATP, 0.33 mM AMARA
peptide, 0.05 µCi/µl [γ32]ATP, pH 7.0. Laemmli’s Buffer: (18). PBS: 140 mM NaCl,
2.7 mM KCl, 2.1 mM KH2PO4, 9.9 mM Na2HPO4, pH 7.3. PBST: PBS with 1%
Tween-20.
Materials. General reagents were obtained from Sigma-Aldrich Chemical (St.
Louis, MO) unless otherwise stated. G6P, F6P, F1,6-P2, 3PG, G1P, G1,6-P2, ADP,
Carn, Acarn, IMP, and inosine were obtained from Sigma-Aldrich Chemical.
Ammonium acetate was obtained from Merck KGaA (Darmstadt, Germany).
Recombinant LKB1-STRAD-MO25 lot no. 28640AU (0.1 µg/µl, 34 units/mg) and
LKB1tide were obtained from Upstate (Charleston, VA). His-bind nickel-binding
resin was obtained from Novagen (Madison, WI). Western blotting primary
antibodies were obtained from Cell Signaling Technologies (Danvers, MA). Resins
for chromatographic purification, secondary antibody for Western blotting, and ECL
detection solution were obtained from Amersham Biosciences (Piscataway, NJ).
Generation and Purification of Recombinant AMPK. Bacteria expressing
recombinant α2β2γ2 and α1β1γ1 AMPK were prepared as previously described (22,
23, 34, 35). Recombinant α2β2γ2 and α1β1γ1 AMPK was extracted and purified by
nickel affinity chromatography (36). After buffer exchange into AMPK storage
buffer, recombinant AMPK was concentrated to 1 µg/µl before use for
experimentation. Recombinant α-312 AMPK protein for Western blot analysis was
likewise obtained as previously described (7, 14, 35, 36).
AMPKK and P-AMPK Activity Assays. In all cases, unless otherwise stated,
the AMPK used for experimentation was α2β2γ2 AMPK. AMPKK activity was
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measured in a two-step assay. In the first step, AMPK was phosphorylated and
activated by LKB1-STRAD-MO25. In the second step, P-AMPK phosphorylated
AMARA peptide (10). Recombinant α2β2γ2-AMPK was diluted 1:19 in water and
α1β1γ1 was diluted 1:9 in water. Recombinant LKB1-STRAD-MO25 (0.1 µg/µl) was
diluted 1:39 in AMPK storage buffer. The metabolites, G6P, F6P, F1,6P2, 3PG, G1P,
G1,6P2, ADP, Carn, Acarn, inosine, IMP, and ammonia were individually dissolved in
water at 5x the desired final concentration before the first step of the reaction. G6P,
F6P, ADP, and IMP were all controlled for their sodium content as previously
described (34) and G1P was controlled for potassium in the same manner. For the
assay, 4 µl of AMPK phosphorylation buffer were mixed with 2 µl of diluted
recombinant AMPK, 2 µl of the testing compound, and 2 µl of AMPKK and allowed
to incubate for 20 min at 30°C. After the incubation, 15 µl of AMARA
phosphorylation buffer was added to the mixture to start the second step of the assay
and allowed to incubate for an additional 10 min at 30°C. At the conclusion of the 10
min, the reaction was stopped by spotting 15 µl of the final reaction mixture on a 1cm2
piece of Whatman P81 filter paper. Filter papers were allowed to absorb the reaction
mix for 15 sec and then were placed in 100 ml of 1% phosphoric acid. The papers
were washed in the acid six times and then briefly in acetone. After drying, the papers
were then placed in 3 ml of Ecolite scintillation fluid and radioactivity was determined
in a liquid scintillation counter for 1 min.
Assays to measure the effects of ADP and 3PG on P-AMPK were performed
the same as the AMPKK activity assay with the following changes. 2 µl of water were
added before the start of the first reaction instead of 5x ADP or 3PG. The first
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reaction was allowed to proceed for 30 min to allow for full phosphorylation of
AMPK. The ADP or 3PG was added at the start of the second reaction.
For assays to determine the activity of LKB1-STRAD-MO25 in
phosphorylating LKB1tide, 450 µl AMPK phosphorylation buffer, 225 µl of 0.775 mM
LKB1tide in water, 135 µl of water, and 4 µl of [γ32P]ATP were combined and 18 µl
of this mixture were loaded together with 5X 3PG as above. The reaction was started
with the addition of 2 µl recombinant LKB1-STRAD-MO25 diluted 1:4 in AMPK
storage buffer and stopped by spotting the reaction mixture onto filter papers and
continuing as above.
Western Blot. The first step of the AMPKK assay was performed, but with a
30 min incubation. After the incubation period, the reaction was stopped by addition
of diluted 4 x Laemmli’s buffer and water (1:1:2). Proteins in the reaction mixture
were then separated by SDS-PAGE at 200 V for 50 minutes in 7.5% Tris-HCl, 30 µl
well, Criterion Precast Gels (Bio-Rad, Hercules CA). Proteins were
electrophoretically transferred from the gels to PVDF membranes at 100 V for 60 min.
Membranes were blocked in PBST and 5% Blotting Grade Blocker Non-Fat Dry Milk
for 1 hour. Membranes were incubated overnight at 4°C in PBST, 5% blocking milk,
and primary antibody. After incubation with a rabbit anti-P-AMPK antibody,
membranes were washed twice with PBST for 10 minutes and twice with PBS for 5
minutes. Membranes were then incubated for 1 hour at room temperature in PBST,
3% blocking milk, and a secondary antibody. Following incubation with an HRPlinked anti-rabbit antibody, membranes were washed twice with PBST for 10 minutes
and twice with PBS for 5 minutes. Membranes were covered with ECL Western
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Blotting Detection Reagent, enclosed in transparent plastic sheets, and visualized on
Classic Blue Autoradiography film. Relative amounts of protein were quantified by
measuring spot size and intensity with AlphaEaseFC software (Alpha Innotech
Corporation, San Leandro CA).
Statistics. The effects of each metabolite on AMPKK activity, assays testing
effects of ADP and 3PG on AMPKK and P-AMPK activity, assays of AMPKK
activity against α1β1γ1 AMPK in the presence of 3PG, Western blot analysis of 3PG
mediated AMPK and α-312 AMPK activation, and AMPKK activity assays against
LKB1tide were all compared by one-way ANOVA. Post hoc comparisons were
performed using Fisher’s least significant difference multiple comparison test. For
Western blotting of the inhibitory effect of ADP on AMPK phosphorylation, and
comparisons of Vmax and K0.5 of the substrate-activation curves, Student’s t-tests were
used to test for statistical significance. For all statistical tests, significance was set at p
< 0.05. All statistical procedures were performed using the NCSS statistical program
(Kaysville, UT). All data are reported as means ± SE.

RESULTS
To test the hypothesis that an intracellular metabolite demonstrates allosteric
control of the phosphorylation of AMPK, we assayed the AMPKK activity of LKB1STRAD-MO25 in the presence of each of the following compounds: G6P, F6P,
F1,6P2, 3PG, G1P, G1,6P2, ADP, Carn, Acarn, inosine, IMP, and ammonia. Each
metabolite was assayed at concentrations typical of resting conditions and exercising
conditions (Fig. 1A−D, n = 5−6). Resting concentrations for all metabolites except
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Carn were determined by taking the lowest values cited in the primary literature.
Likewise, exercising concentrations were determined by taking the highest values
cited. Given that Carn concentrations decrease during exercise, the resting
concentration was found by taking the highest value, and the exercising concentration
was found by taking the lowest value found in the primary literature. Addition of
ADP at both resting and exercising concentrations resulted in a marked inhibition of
LKB1-STRAD-MO25 activity, while addition of Carn at the resting concentration
resulted in slight inhibition of LKB1-STRAD-MO25 activity (Fig. 1B). Addition of
3PG at the exercising concentration resulted in an increase in LKB1-STRAD-MO25
activity (Fig. 1D). Addition of all other metabolites had no effect on LKB1-STRADMO25 activity.
Given that the AMPKK assay is a two-step assay, with the metabolite being
added at the beginning of the first step, it is possible that ADP and 3PG exhibit their
effects on P-AMPK rather than LKB1-STRAD-MO25. To test this, two assays were
performed. The first was done the same as the previous assays, but with ADP at
concentrations of 0, 0.2, 0.4, 0.6, 0.8, and 1.0 mM. In the second assay, we fully
phosphorylated AMPK and then added ADP at the same concentrations at the start of
the second reaction. ADP had an inhibitory effect under both conditions, but the
effect was greater in the first assay (Fig. 2A, n = 6).
Because the P-AMPK assay showed ADP to inhibit P-AMPK activity, but
demonstrated an inhibition of approximately 22% less than what was seen in the
AMPKK assay, it was possible that ADP was inhibiting both P-AMPK and LKB1STRAD-MO25 activities. To test this, a Western blot was performed. We incubated
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LKB1-STRAD-MO25 with AMPK at ADP concentrations of 0 or 0.8 mM, stopped
the reaction with Laemmli’s buffer, and Western blotted for P-AMPK (Fig. 2B, n = 8).
Addition of 0.8 mM ADP reduced P-AMPK quantities by approximately 22%.
AMPKK and P-AMPK assays were also performed in the presence of 0, 0.5,
2.5, 5.0, 7.5, and 10.0 mM 3PG concentrations to test if it stimulates either LKB1STRAD-MO25 or P-AMPK activities. 3PG had a stimulatory effect on LKB1STRAD-MO25 activity, but no effect on P-AMPK activity (Fig. 3A, n = 5-6). To
validate the AMPKK assay by directly measuring the LKB1-STRAD-MO25 activity
towards AMPK, Western blotting was performed. We incubated LKB1-STRADMO25 with AMPK at 3PG concentrations of 0, 0.5, 2.5, 5.0, 7.5, and 10.0 mM,
stopped the reaction with Laemmli’s buffer, and Western blotted for P-AMPK. 3PG
stimulated LKB1-STRAD-MO25 activity in the same pattern as was seen in the
AMPKK activity assays (Fig. 3B, n = 7-8). To test whether the stimulatory effect that
3PG has on LKB1-STRAD-MO25 is specific to the AMPK isoform used as a
substrate, AMPKK assays were performed using α1β1γ1 AMPK at 3PG
concentrations 0, 0.5, 2.5, 5.0, 7.5, and 10.0 mM. 3PG was found to have a similar
effect on α1β1γ1 AMPK activation, as it did on α2β2γ2 AMPK activation. Analysis
was also performed on these blots to obtain a Hill coefficient, Vmax, and Ka (Fig. 4).
The Vmax was determined to be 157.0 ± 12.4 units, the Ka was found to be 1.50 ± 0.28
mM 3PG, and the Hill coefficient was found to be 1.49 ± 0.26. The best fit line was
calculated using the average value at each data point.
To test whether 3PG is able to cause an LKB1-STRAD-MO25-mediated
activation of a non-AMPK substrate, or whether 3PG has a substrate-specific
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stimulatory effect, we tested LKB1-STRAD-MO25 activity against the peptide
substrate, LKB1tide at 3PG concentrations of 0 and 7.5 mM. Preliminary tests
showed that 3PG had an inhibitory effect on LKB1-STRAD-MO25 activity towards
LKB1tide. To ensure that the inhibitory effect was not caused by the sodium found in
the 3PG, additional assays were performed with sodium acetate at 15.0 mM. We
found again that 3PG has an inhibitory effect, and that the inhibition is not due to the
presence of sodium (Fig. 5, n = 6).
We investigated the necessity of the β and γ – AMPK subunits in LKB1STRAD-MO25 activation of AMPK. Western blotting was done with LKB1STRAD-MO25 incubated with truncated α-312 AMPK in the presence of 0.0, 0.5, 2.5,
5.0, 7.5, and 10.0 mM 3PG. Analysis with anti-P-AMPK antibody detected a
progressive increase in P-AMPK as a function of 3PG concentration, with a maximal
increase of approximately 3-fold seen at 5 mM 3PG (Fig. 6, n = 8).
Western blots were also done to investigate a possible allosteric interaction of
3PG. P-AMPK blots were performed at ATP concentrations of 0.0, 0.01, 0.025, 0.05,
0.1, 0.2, and 1.0 mM, and with or without 7.5 mM 3PG. Both 0.0 and 7.5 mM 3PG
curves demonstrated a sigmoidal curve. The Vmax for LKB1-STRAD-MO25 in the
absence of 3PG was 356 ± 13.9 relative units and the K0.5 was 85.6 ± 14.3 nM ATP.
The Vmax for LKB1-STRAD-MO25 in the presence of 7.5 mM 3PG was 468 ± 23.2
relative units and the K0.5 was 55.8 ± 5.36 nM ATP (Fig. 7, n = 8).
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DISCUSSION
Previous studies dealing with AMPKK activity and AMPK activation during
exercise have produced data that appear to be contradictory. Previous studies have
demonstrated a contraction-induced increase in phosphorylation of AMPK (24, 15, 39,
43) without concurrent detectable increases in AMPKK activity (14, 28). This
discrepancy could be explained by the presence of intramuscular allosteric activators
that increase in response to contraction. These activators would not be retained in the
PEG precipitates utilized for determination of AMPKK activity. Very little is
currently known about allosteric regulation of the LKB1-STRAD-MO25/AMPK
system. Initial understanding of AMPK claimed that creatine phosphate (CrP) acted
as an allosteric inhibitor of AMPK (25, 40); however, a recent study from our lab
produced evidence against that concept (34). Another report from our lab
demonstrated that long-chain acyl-CoA esters, such as palmitoyl-CoA, inhibit
AMPKK activity, and that palmitoylcarnitine may act as an allosteric activator (35).
In our current study we tested, in vitro, an array of metabolites at concentrations
typical of both resting and exercising conditions in an attempt to discover an allosteric
regulator.
From our first set of experiments, our data suggest that Carn, ADP, and 3PG
all have some type of effect on LKB1-STRAD-MO25 activity (Fig. 1B and D). We
first investigated the drastic inhibition seen when LKB1-STRAD-MO25 and AMPK
were incubated with ADP. Controlling for the presence of sodium in the ADP, both
our AMPKK assay and our P-AMPK assay showed an ADP dose-dependent inhibition
(Fig. 2A). Because in the AMPKK assay, the ADP was added at the beginning of the
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first step of the two-step assay and was still present during the second step, ADP could
possibly be inhibiting P-AMPK, and not AMPKK. The P-AMPK assay showed a
similar decrease in activity, which indicates that ADP is inhibiting the activity of PAMPK against its substrate, the AMARA peptide. However, there is a discrepancy in
the extent that ADP caused inhibition between the AMPKK assay and the P-AMPK
assay. At an ADP concentration of 0.8 mM, an approximately 22% difference is seen
between the two assay curves. This difference could be explained by an inhibition of
the LKB1-STRAD-MO25 complex as well. Western blot analysis confirmed that
ADP indeed does inhibit the phosphorylation of AMPK by LKB1-STRAD-MO25
(Fig. 2B). We conclude that ADP is able to inhibit both P-AMPK, and to a lesser
extent, LKB1-STRAD-MO25 activity towards AMPK.
Both our AMPKK assays and our Western blots clearly showed that 3PG acts
as an activator of LKB1-STRAD-MO25 activity. Our P-AMPK assay also showed
that 3PG has no significant effect on the activity of activated-AMPK. These results
suggest that when an individual undergoes a bout of exercise, the change in the
concentration of 3PG allows for the LKB1-STRAD-MO25 complex to more readily
phosphorylate skeletal muscle AMPK. This effect, however, may not be isolated only
to working skeletal muscle. Our AMPKK assay using α1β1γ1 AMPK as a substrate
demonstrated a similar stimulatory response to increased 3PG levels (Fig. 3C). Given
that very little information is available on the concentrations of 3PG during resting and
exercising conditions in non-skeletal muscle sources, we can not declare with certainty
that this new found effect will occur outside skeletal muscle, such as the liver;
however, it does remain a possibility.
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Using the Western blot data from Figure 3B, a Hill coefficient was calculated.
While recognizing Western blotting to represent a non-precise method of quantitation,
a crude estimation of the activation constant (Ka) and Hill coefficient can be obtained.
Though the method was crude, we were able to gain a general understanding from our
analysis. Our calculated Hill coefficient of 1.49 ± 0.26 leads us to believe that 3PG
exhibits mild cooperativity. Our calculated Ka for 3PG of 1.50 ± 0.28 lies well within
the range of fluctuations in concentration expected to be observed between resting and
contracting muscle.
We performed a number of experiments in an attempt to discern where 3PG
was inducing its stimulatory effect. 3PG has the possibility of acting on either the
LKB1-STRAD-MO25 complex, allowing it to phosphorylate AMPK better, or it could
act on AMPK itself, causing AMPK to undergo a change, making it a better substrate
for phosphorylation by the LKB1-STRAD-MO25 complex. Our evidence suggests
that 3PG enhancement of LKB1-STRAD-MO25 activity is specific to AMPK as a
substrate. AMPK is one of 14 kinases that have been found to be directly
phosphorylated by LKB1 (19). The peptide LKB1tide corresponds to an amino acid
sequence of another of the 14 kinases, NUAK2. LKB1-STRAD-MO25 activity
against LKB1tide was inhibited by 7.5 mM 3PG, suggesting that the effect is specific
to AMPK (Fig. 5). Likewise, AMPK phosphorylation was further enhanced when we
used the truncated AMPK α-312 subunit as shown by Western blot analysis. When
we used the full α2β2γ2 AMPK as a substrate, maximal AMPK phosphorylation
yielded an increase of approximately 160% (Fig. 3B), while the maximal increase in
phosphorylation of the α-312 AMPK reached nearly 300% (Fig. 6). These data
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suggest that 1) the β and γ AMPK subunits are not necessary for 3PG mediated
enhancement of LKB1-STRAD-MO25 activity, and that 2) 3PG will either bind to the
α AMPK subunit, or to the LKB1-STRAD-MO25 complex. In sum, while our data
suggest that 3PG causes a substrate specific enhancement of LKB1-STRAD-MO25
activity, we can not definitively conclude that the effect was specific to AMPK.
Further investigation of the effect of 3PG on multiple LKB1 substrates, as well as
binding affinity experiments, would need to be performed in order to make such a
conclusion. Furthermore, we were unable to conclude from our data where 3PG
binding was occurring.
Regardless of the location of the 3PG binding, we present clear evidence as to
the type of interaction that 3PG has with whichever enzyme it binds to (Fig. 7). First,
we demonstrate the allosteric nature of ATP, in regards to the LKB1-STRAD-MO25
complex. The curve shown in Figure 7 clearly has a sigmoidal shape, which is
consistent with allosteric enzymes. As well, we show that the maximal velocity of
LKB1-STRAD-MO25 is reached at no more than 1.0 mM ATP. Preliminary tests
showed that incubation with concentrations of 2.0 and 4.0 mM ATP yielded velocities
which were not significantly different than at 1.0 mM ATP (data not shown). LKB1STRAD-MO25 without any additional modulators was able to reach a Vmax of 356 ±
13.9 relative units, with a K0.5 of 85.6 ± 14.3 nM ATP. At a 3PG concentration of 7.5
mM, and with the same increasing concentrations of ATP, a sigmoidal curve was also
observed. The Vmax of this curve was 468 ± 23.2 relative units, with a K0.5 of 55.8 ±
5.36 nM ATP. Comparing the two curves, the Vmax of each curve is significantly
different than the other, while the K0.5 of each curve is not significantly different than
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the other. These results are consistent with allosteric activators; we believe that the
data presented are sufficient to conclude that 3PG is an allosteric modulator of LKB1STRAD-MO25 activity.
We now propose a physiologic rationale for having 3PG as an activator of the
AMPK pathway. 3PG could be acting as an energy utilization switch. At the onset of
exercise, the predominant energy substrate used in skeletal muscle is glycogen. This
glycogen is broken down to G6P, which then enters glycolysis. Further down the
glycolytic pathway, 3PG will be formed. As more glycogen is continually broken
down in the first moments of exercise, 3PG levels will continue to increase and will
stimulate LKB1-STRAD-MO25 activity. This increase in LKB1-STRAD-MO25
activity will then activate AMPK and allow for blood glucose to be transported into
the muscle. As exercise continues, the 3PG-induced elevation in AMPK activity will
cause phosphorylation and inactivation of ACC, causing malonyl-CoA to decrease and
allowing an increase in fatty acid oxidation as fatty acids become available. In short,
this model suggests that 3PG contributes to AMPK activation, acting as a switch to
turn on blood glucose utilization near the beginning of exercise, and allowing for more
fatty acids to be oxidized as exercise continues over time.
In summary, we found that a majority of the metabolites that we investigated
had no effect on LKB1-STRAD-MO25 activity. ADP had a partial inhibitory effect
on LKB1-STRAD-MO25 activity, but a more pronounced effect on P-AMPK activity.
Carnitine had an effect on LKB1-STRAD-MO25 while 3PG had a larger effect.
While it seems clear that 3PG is an allosteric modulator of LKB1-STRAD-MO25
activity, we are unsure whether its effect is on the LKB1-STRAD-MO25 complex, or
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whether the effect occurs within the first 312 residues of the α-AMPK subunit.
Physiologically, 3PG may act as an energy substrate utilization sensor, or in some
other capacity. Regardless, the discovery of an LKB1-STRAD-MO25 allosteric
modulator appears to clarify why previous studies have shown contradictory evidence
of exercise-induced decreases in AMPKK activity along with increased AMPK
phosphorylation, and is generally important as we continue to learn and understand the
AMPK signaling cascade.
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FIGURE LEGENDS

Figure 1. AMPKK activities of LKB1-STRAD-MO25 against AMPK in the presence
of various metabolites at concentrations typical of resting and exercising values. (A)
inosine: 0.005 mM, 0.25 mM; IMP: 0.5 mM, 5.0 mM; ammonia: 0.05 mM, 0.5 mM.
(B) Carn: 3.5 mM, 1.0 mM; Acarn: 0.5 mM, 5.0 mM; ADP 0.4 mM, 0.8 mM. (C)
G6P: 0.05 mM, 2.0 mM; G1P: 0.1 mM, 0.4 mM; G1,6P2: 0.075 mM, 0.5 mM. (D)
F6P: 0.02 mM, 0.15 mM; F1,6P2: 0.04 mM, 0.2 mM; 3PG: 0.5 mM, 1.5 mM.
Concentrations of each metabolite are listed in the order of resting concentration, then
exercising concentration. *Activity at these concentrations was significantly different
from the respective 0 mM concentration (n = 5-6, p < 0.05).

Figure 2. Inhibition of AMPKK activity of LKB1-STRAD-MO25 and P-AMPK
activity by ADP. (A) Assays of both AMPKK activity and P-AMPK activity in the
presence of 0.0, 0.2, 0.4, 0.6, 0.8, or 1.0 mM ADP. (B) Measurement of ADP
inhibition of LKB1-STRAD-MO25 by Western blot analysis of P-AMPK. LKB1STRAD-MO25 and AMPK were incubated in the presence of 0.0 or 0.8 mM ADP.
All control values were normalized to 1. †Significantly different than AMPKK assay
(p < 0.05). *Denotes a significant difference from the control (n = 5-8, p < 0.05).

Figure 3. Stimulatory effect of 3PG on AMPKK activity of LKB1-STRAD-MO25
mediated AMPK activation. Concentrations of 3PG used in all experiments were 0.0,
0.5, 2.5, 5.0, 7.5 and 10.0 mM. (A) Assays of both AMPKK activity and P-AMPK
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activity in the presence of 3PG. (B) Western blot validation of the stimulatory effect
of 3PG on AMPKK activity. (C) Stimulation of AMPKK activity by 3PG is not
confined to muscle-specific AMPK. AMPKK assay was performed using α1β1γ1
AMPK as a substrate. Control values were normalized to 1. †Significantly different
than P-AMPK assay (p < 0.05). *Significant difference from control was observed at
these concentrations (n = 5-8, p < 0.05)

Figure 4. Hill equation analysis of the effects of 3PG on AMPK phosphorylation.
Vmax = 157.0 ± 12.4, Ka = 1.5 ± 0.28, Hill coefficient = 1.49 ± 0.26. Data points were
calculated using data from Western blots of Figure 3B. The line of best fit was
determined using the Grafit Program from the increases in activity above the 0 mM
3PG group.

Figure 5. AMPKK activity of LKB1-STRAD-MO25 in phosphorylating LKB1tide in
the presence of 7.5 mM 3PG and 15.0 mM sodium acetate (SA). SA was used to
verify that the observed inhibition was not due to the sodium content of 3PG. Control
values normalized to 1. *Significantly different from control (n = 6, p < 0.05).

Figure 6. Activation of truncated AMPK (α-312) by LKB1-STRAD-MO25 in the
presence of 0.0, 0.5, 2.5, 5.0, 7.5, and 10.0 mM 3PG. Control was normalized to 1.
*Significantly different than control (n = 8, p < 0.05).
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Figure 7. Substrate-activity curves for LKB1-STRAD-MO25 activity against AMPK.
ATP was the substrate used at concentrations of 0.0, 0.01, 0.025, 0.05, 0.1, 0.2, and
1.0 mM. 0.0 or 7.5 mM 3PG were used to demonstrate 3PG as a positive allosteric
modulator. For 0.0 mM 3PG curve, the Vmax was 356 ± 13.9, and K0.5 was 85.6 ± 14.3
nM ATP. For 7.5 mM 3PG curve, the Vmax was 468 ± 13.9, and K0.5 was 55.8 ± 5.36
nM ATP. Vmax for the curves were significantly different while the K0.5 for the curves
was not. Significance was established as p < 0.05, n = 8.
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